

# Executive Branch Personnel

## Public Financial Disclosure Report:

### Periodic Transaction Report (OGE Form 278-T)

#### Filer's Information

---

Petsonk, Carol

Deputy Assistant Secretary for Aviation and International Affairs, Department of Transportation

---

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Petsonk, Carol [electronically signed on 05/06/2022 by Petsonk, Carol in Integrity.gov]

---

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Carlson, Terence W, Certifying Official [electronically signed on 06/02/2022 by Carlson, Terence W in Integrity.gov]

---

Other review conducted by

/s/ Deavers, Lynn, Ethics Official [electronically signed on 05/10/2022 by Deavers, Lynn in Integrity.gov]

---

U.S. Office of Government Ethics Certification

---

#### Transactions

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	Nutrien, Ltd. (NTR)	Sale	04/07/2022	No	\$15,001 - \$50,000
2	HDFC Bank Limited ADS (HDB)	Purchase	04/07/2022	No	\$50,001 - \$100,000
3	JD.com ADS (JD)	Purchase	04/07/2022	No	\$15,001 - \$50,000
4	KS CSI China Internet ETF (KWEB)	Sale	04/07/2022	No	\$15,001 - \$50,000
5	Nutrien, Ltd. (NTR)	Sale	04/07/2022	No	\$1,001 - \$15,000
6	BGC Partners, Inc. (BGCP)	Sale	04/08/2022	No	\$1,001 - \$15,000
7	JD.com ADS (JD)	Purchase	04/08/2022	No	\$15,001 - \$50,000
8	KS CSI China Internet ETF (KWEB)	Sale	04/08/2022	No	\$15,001 - \$50,000
9	Inhibrx, Inc. (INBX)	Purchase	04/08/2022	No	\$15,001 - \$50,000
10	BGC Partners, Inc. (BGCP)	Sale	04/11/2022	No	\$1,001 - \$15,000
11	JD.com ADS (JD)	Purchase	04/11/2022	No	\$15,001 - \$50,000
12	KS CSI China Internet ETF (KWEB)	Sale	04/11/2022	No	\$15,001 - \$50,000
13	Nutrien, Ltd. (NTR)	Sale	04/11/2022	No	\$1,001 - \$15,000
14	Merck & Co., Inc. (MRK)	Sale	04/11/2022	No	\$50,001 - \$100,000
15	Inhibrx, Inc. (INBX)	Purchase	04/11/2022	No	\$15,001 - \$50,000
16	Merck & Co., Inc. (MRK)	Sale	04/13/2022	No	\$1,001 - \$15,000
17	Inhibrx, Inc. (INBX)	Purchase	04/14/2022	No	\$1,001 - \$15,000
18	Merck & Co., Inc. (MRK)	Sale	04/13/2022	No	\$1,001 - \$15,000
19	Inhibrx, Inc. (INBX)	Purchase	04/13/2022	No	\$1,001 - \$15,000
20	Merck & Co., Inc. (MRK)	Sale	04/14/2022	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
21	Inhibrx, Inc. (INBX)	Purchase	04/14/2022	No	\$1,001 - \$15,000
22	HDFC Bank Limited ADS (HDB) ADS	Purchase	04/19/2022	No	\$1,001 - \$15,000
23	Bristol-Myers Squibb (BMY)	Sale	04/19/2022	No	\$1,001 - \$15,000
24	Inhibrx, Inc. (INBX)	Purchase	04/20/2022	No	\$1,001 - \$15,000
25	Bristol-Myers Squibb (BMY)	Sale	04/20/2022	No	\$1,001 - \$15,000
26	Inhibrx, Inc. (INBX)	Purchase	04/20/2022	No	\$1,001 - \$15,000
27	Bristol-Myers Squibb (BMY)	Sale	04/20/2022	No	\$1,001 - \$15,000
28	Inhibrx, Inc. (INBX)	Purchase	04/11/2022	No	\$15,001 - \$50,000
29	Inhibrx, Inc. (INBX)	Purchase	04/21/2022	No	\$1,001 - \$15,000
30	Bristol-Myers Squibb (BMY)	Sale	04/21/2022	No	\$1,001 - \$15,000
31	Inhibrx, Inc. (INBX)	Purchase	04/21/2022	No	\$1,001 - \$15,000
32	Bristol-Myers Squibb (BMY)	Sale	04/21/2022	No	\$1,001 - \$15,000
33	Inhibrx, Inc. (INBX)	Purchase	04/25/2022	No	\$1,001 - \$15,000
34	Bristol-Myers Squibb (BMY)	Sale	04/25/2022	No	\$1,001 - \$15,000
35	Inhibrx, Inc. (INBX)	Purchase	04/26/2022	No	\$1,001 - \$15,000
36	Bristol-Myers Squibb (BMY)	Sale	04/26/2022	No	\$1,001 - \$15,000
37	Pfizer Inc. (PFE)	Purchase	04/26/2022	No	\$1,001 - \$15,000
38	Bristol-Myers Squibb (BMY)	Sale	04/26/2022	No	\$1,001 - \$15,000
39	Inhibrx, Inc. (INBX)	Purchase	04/26/2022	No	\$1,001 - \$15,000
40	Bristol-Myers Squibb (BMY)	Sale	04/26/2022	No	\$1,001 - \$15,000
41	Inhibrx, Inc. (INBX)	Purchase	04/28/2022	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
42	Pfizer Inc. (PFE)	Purchase	04/28/2022	No	\$1,001 - \$15,000
43	StoneCo Ltd. ADS (STNE)	Purchase	04/28/2022	No	\$1,001 - \$15,000
44	Inhibrx, Inc. (INBX)	Purchase	04/29/2022	No	\$1,001 - \$15,000
45	Bristol-Myers Squibb (BMY)	Sale	04/29/2022	No	\$1,001 - \$15,000
46	StoneCo. Ltd. ADS (STNE)	Purchase	04/29/2022	No	\$1,001 - \$15,000
47	Global Payments, Inc. (GPN)	Sale	05/03/2022	No	\$1,001 - \$15,000
48	Inhibrx, Inc. (INBX)	Purchase	05/04/2022	No	\$1,001 - \$15,000
49	Bristol-Myers Squibb (BMY)	Sale	05/04/2022	No	\$1,001 - \$15,000
50	Inhibrx, Inc. (INBX)	Purchase	05/04/2022	No	\$1,001 - \$15,000
51	Bristol-Myers Squibb (BMY)	Sale	05/04/2022	No	\$1,001 - \$15,000
52	Inhibrx, Inc. (INBX)	Purchase	05/04/2022	No	\$1,001 - \$15,000
53	Bristol-Myers Squibb (BMY)	Sale	05/04/2022	No	\$1,001 - \$15,000
54	Inhibrx, Inc. (INBX)	Purchase	05/04/2022	No	\$1,001 - \$15,000

## Endnotes

## Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. Failure to provide the requested information may result in separation, disciplinary action, or civil action. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (4) to the National Archives and Records Administration or the General Services Administration in records management inspections; (5) to the Office of Management and Budget during legislative coordination on private relief legislation; (6) when the disclosing agency determines that the records are arguably relevant to a proceeding before a court, grand jury, or administrative or adjudicative body, or in a proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant to the proceeding; (7) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another, a public financial disclosure report and any accompanying documents, including statements notifying an employee's supervising ethics office of the commencement of negotiations for future employment or compensation or of an agreement for future employment or compensation; (8) to a Member of Congress or a congressional office in response to an inquiry made on behalf of and at the request of an individual who is the subject of the record; (9) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to this system of records; (10) on the OGE Website and to any person, department or agency, any written ethics agreement, including certifications of ethics agreement compliance, filed with OGE by an individual nominated by the President to a position requiring Senate confirmation; (11) on the OGE Website and to any person, department or agency, any certificate of divestiture issued by OGE; (12) on the OGE Website and to any person, department or agency, any waiver of the restrictions contained in Executive Order 13770 or any superseding executive order; (13) to appropriate agencies, entities and persons when there has been a suspected or confirmed breach of the system of records, the agency maintaining the records has determined that there is a risk of harm to individuals, the agency, the Federal Government, or national security, and the disclosure is reasonably necessary to assist in connection with the agency's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm; and (14) to another Federal agency or Federal entity, when the agency maintaining the record determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in responding to a suspected or confirmed breach or in preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity, the Federal Government, or national security. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.

---